Celularity Inc. (CELUW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Celularity Inc. (CELUW) Healthcare & Pipeline Overview

Celularity Inc. is a clinical-stage biotechnology company developing "off-the-shelf" allogeneic cell therapies from placentas for cancers, immune disorders, and infectious diseases. Its pipeline includes CAR-T and NK cell therapies, alongside commercial products like Biovance and Interfyl, and biobanking services, positioning it in the regenerative medicine and cell therapy markets.

What Is the Investment Thesis for CELUW?

Celularity Inc. presents an investment thesis centered on its innovative "off-the-shelf" allogeneic cell therapy platform, leveraging placental-derived cells for a broad range of indications including cancer, immune disorders, and infectious diseases. The company's diverse pipeline, featuring candidates like CYCART-19, CYNK-001, and CYNK-101 in Phase I/IIa trials, demonstrates a multi-pronged approach to high-unmet-need therapeutic areas. The potential for these therapies to offer advantages over autologous treatments, such as scalability and immediate availability, represents a significant value driver. Furthermore, existing commercial products like Biovance and Interfyl, alongside its LifebankUSA biobanking service, provide diversified revenue streams, albeit with a current negative profit margin of -345.4%. Key growth catalysts include successful advancement through clinical trial phases, potential regulatory approvals, and expansion of its commercial product portfolio. However, the company's very low market capitalization of $163,857 and early-stage pipeline introduce substantial financial instability and volatility risks, necessitating close monitoring of clinical results and future funding activities.

Based on FMP financials and quantitative analysis

CELUW Key Highlights

Market Capitalization: Reported at $163,857, indicating a very low valuation and potential for high volatility.

• Profit Margin: A negative profit margin of -345.4% reflects the company's current clinical-stage status and significant investment in R&D.
• Gross Margin: A strong gross margin of 76.0% suggests efficient cost management for its commercial products and services.
• Beta: A beta of 0.48 indicates lower volatility relative to the broader market, which is notable for a clinical-stage biotech.
• Employee Base: Operates with a team of 120 employees, focusing resources on its specialized cell therapy development and biobanking operations.

Who Are CELUW's Competitors?

CELUW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CELUW's Key Strengths?

Innovative "off-the-shelf" allogeneic cell therapy platform derived from placentas.

• Diverse pipeline targeting multiple high-unmet-need areas (cancer, immune, infectious, degenerative diseases).
• Existing commercial products (Biovance, Interfyl) and a biobanking service (LifebankUSA) providing diversified operations.
• Strong gross margin (76.0%) on existing commercial activities.

What Are CELUW's Weaknesses?

Very low market capitalization ($163,857) indicating financial instability and high volatility.

• Significant negative profit margin (-345.4%) reflecting high R&D costs and early-stage development.
• All lead therapeutic candidates are in early clinical stages (Phase I/IIa), implying long development timelines and high risk of failure.
• Reliance on future funding activities to sustain operations and advance pipeline.

What Could Drive CELUW Stock Higher?

CELUW catalyst: Announcement of Phase I clinical trial results for CYCART-19 in B-cell malignancies, expected to provide initial efficacy and safety data for the placental-derived CAR-T therapy.

• Progression of CYNK-001 into later-stage clinical trials for acute myeloid leukemia, glioblastoma multiforme, or COVID-19, signaling advancement in its unmodified NK cell platform.
• Initiation of clinical trials for APPL-001 (Crohn's disease) or PDA-002 (facioscapulohumeral muscular dystrophy), transitioning these placenta-derived stromal cell therapies from pre-clinical to human studies.
• Expansion of sales and licensing agreements for commercial products like Biovance and Interfyl, contributing to revenue growth and market penetration in surgical and wound care.

What Are the Key Risks for CELUW?

Financial-distress signal — its Altman Z-Score of -15.11 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Significant financial instability due to a very low market capitalization of $163,857 and a negative profit margin of -345.4%, indicating substantial cash burn and potential need for future financing.
• Clinical trial failures or delays for lead therapeutic candidates (CYCART-19, CYNK-001, CYNK-101), which are all in early phases, could severely impact pipeline viability and investor confidence.
• Intense competition in the cell therapy space from larger, more established pharmaceutical companies and other biotech firms with greater financial resources and more advanced pipelines.
• Regulatory hurdles and the lengthy, complex approval process for novel cell therapies, which can lead to extended development timelines and increased costs.

What Are the Growth Opportunities for CELUW?

• Advancement of CAR-T and NK Cell Therapy Pipeline: Celularity's lead candidates, CYCART-19 (for B-cell malignancies) and CYNK-001 (for AML, glioblastoma, COVID-19), represent significant growth opportunities. The global CAR-T cell therapy market is projected to reach over $20 billion by 2030, while NK cell therapies are gaining traction. Successful progression through Phase I/IIa trials and subsequent phases would validate the placental-derived platform, potentially unlocking substantial market share in oncology and infectious disease, with timelines extending over the next 5-10 years for full commercialization. This platform offers a competitive advantage through its allogeneic, "off-the-shelf" nature.
• Expansion into Degenerative Diseases: The development of APPL-001 for Crohn's disease and PDA-002 for facioscapulohumeral muscular dystrophy positions Celularity to address large, underserved patient populations in degenerative disease. The global market for Crohn's disease treatments alone is expected to exceed $10 billion by 2027. Moving these pre-clinical therapies into clinical trials over the next 2-4 years would open new avenues for growth, leveraging the regenerative potential of placenta-derived mesenchymal-like adherent stromal cells and diversifying the company's therapeutic focus beyond oncology.
• Growth of Commercial Products and Licensing: Celularity currently sells and licenses products like Biovance and Interfyl, which are utilized in the surgical and wound care markets. The global wound care market is estimated to be over $20 billion and growing. Expanding the sales and licensing footprint for these existing commercial products, potentially through new partnerships or indications, offers a more immediate revenue growth opportunity compared to the long development cycles of clinical-stage therapies. This strategy could provide crucial funding and market presence over the next 1-3 years.
• Scaling BioBanking Services (LifebankUSA): The LifebankUSA service, which collects and stores stem cells from umbilical cords and placentas, taps into the growing demand for personalized medicine and regenerative health. The global cord blood banking market is projected to reach over $4 billion by 2027. Expanding the reach and capacity of this biobanking service, potentially through increased consumer awareness, partnerships with healthcare providers, or offering expanded storage options, could provide a stable, recurring revenue stream and enhance brand recognition within the broader regenerative medicine ecosystem over the next 3-5 years.
• Platform Technology Validation and New Indications: The core strength of Celularity lies in its innovative placental-derived cell therapy platform. Successful clinical outcomes for any of its lead candidates could validate this platform, paving the way for rapid expansion into additional therapeutic indications or the development of entirely new product lines. This validation could attract significant partnerships or licensing agreements, accelerating development across multiple disease areas. The long-term potential, spanning 5-15 years, is to establish the placenta as a versatile source for a new generation of allogeneic cellular medicines, addressing a multitude of unmet medical needs.

What Threats Does CELUW Face?

• High attrition rate in clinical trials for cell therapies, leading to potential pipeline failures.
• Intense competition from other biotechnology and pharmaceutical companies developing cell and gene therapies.
• Significant capital requirements for R&D and clinical trials, posing ongoing financing risks.
• Regulatory hurdles and potential delays in obtaining approvals for novel cell therapies.

What Are CELUW's Competitive Advantages?

• Proprietary Placental-Derived Platform: Utilizes a unique source (placentas) for "off-the-shelf" allogeneic cell therapies, potentially offering advantages in scalability and accessibility over autologous approaches.
• Diverse Clinical Pipeline: A broad pipeline targeting multiple therapeutic areas (oncology, infectious disease, degenerative disease) diversifies risk and expands market potential.
• Integrated Business Model: Combines therapeutic development with commercial products (Biovance, Interfyl) and a biobanking service (LifebankUSA), creating multiple revenue streams and a unique ecosystem.
• Intellectual Property: Likely holds patents surrounding its placental cell isolation, expansion, and modification technologies, protecting its innovative processes and products.

What Does CELUW Do?

Celularity Inc., headquartered in Florham Park, New Jersey, is a biotechnology company founded in 2016, dedicated to advancing "off-the-shelf" allogeneic cell therapies derived from placentas. These innovative treatments are being developed to address a spectrum of severe medical conditions, including various cancers, immune system dysfunctions, and infectious illnesses. The company's operational framework is structured into three distinct divisions: Cell Therapy, Degenerative Disease, and BioBanking, reflecting its multi-faceted approach to cellular medicine. In its Cell Therapy division, Celularity boasts a robust pipeline of therapeutic candidates. CYCART-19, a placental-derived CAR-T therapy, is currently undergoing Phase I clinical trials for the treatment of B-cell malignancies. Another key candidate, CYNK-001, an unmodified natural killer (NK) cell also sourced from placentas, is in Phase I trials for acute myeloid leukemia and a Phase I/IIa trial for glioblastoma multiforme and COVID-19. Additionally, CYNK-101, an allogeneic genetically modified NK cell, is progressing through Phase I for HER2-positive gastric and gastroesophageal cancers. The Degenerative Disease division is advancing two placenta-derived mesenchymal-like adherent stromal cell therapies: APPL-001, targeting Crohn's disease, and PDA-002, aimed at facioscapulohumeral muscular dystrophy, both currently in pre-clinical development. Beyond its clinical pipeline, Celularity maintains a commercial presence by selling and licensing products such as Biovance and Interfyl, which are utilized in the surgical and wound care markets. The BioBanking division operates under the LifebankUSA brand, providing essential services for the collection and secure cryogenic storage of stem cells derived from umbilical cords and placentas. With 120 employees, Celularity Inc. is strategically positioned at the intersection of regenerative medicine and advanced cell therapy, leveraging its unique placental platform to develop potentially transformative treatments and services.

What Products and Services Does CELUW Offer?

• Develops "off-the-shelf" allogeneic cell therapies sourced from placentas.
• Conducts clinical trials for therapies targeting various cancers, immune dysfunctions, and infectious illnesses.
• Advances placental-derived CAR-T therapy (CYCART-19) for B-cell malignancies.
• Investigates unmodified natural killer (NK) cells (CYNK-001) for acute myeloid leukemia, glioblastoma, and COVID-19.
• Develops genetically modified NK cells (CYNK-101) for HER2-positive gastric and gastroesophageal cancers.
• Progresses mesenchymal-like adherent stromal cell therapies (APPL-001, PDA-002) for degenerative diseases.
• Sells and licenses commercial products like Biovance and Interfyl for surgical and wound care.
• Operates LifebankUSA, a service for collecting and storing umbilical cord and placenta stem cells.

How Does CELUW Make Money?

• Generates revenue through the sale and licensing of commercial products like Biovance and Interfyl in surgical and wound care markets.
• Earns service fees from its LifebankUSA biobanking operation for collecting and storing stem cells.
• Aims for future revenue generation through the successful development, regulatory approval, and commercialization of its clinical-stage cell therapies.
• Potentially secures milestone payments and royalties from partnerships or licensing agreements related to its therapeutic pipeline.

What Industry Does CELUW Operate In?

Celularity Inc. operates within the dynamic and rapidly evolving biotechnology industry, specifically focusing on the cell therapy and regenerative medicine segments. The broader biotechnology market is characterized by significant R&D investment, long development cycles, and high regulatory hurdles, but also holds the promise of transformative treatments for severe diseases. The global cell therapy market, valued at approximately $10 billion in 2022, is projected to grow substantially, driven by advancements in CAR-T and NK cell therapies, and increasing prevalence of chronic diseases. Celularity's unique positioning stems from its "off-the-shelf" allogeneic approach using placental-derived cells, which aims to overcome the logistical and cost challenges associated with autologous therapies. This differentiates it within a competitive landscape that includes both large pharmaceutical companies with cell therapy divisions and numerous smaller biotech firms specializing in various cellular approaches. The company's dual focus on therapeutic development and biobanking services further diversifies its engagement within the healthcare ecosystem.

Who Are CELUW's Key Customers?

• Healthcare providers and surgical centers utilizing Biovance and Interfyl for wound care and surgical applications.
• Expectant parents and families seeking to collect and store umbilical cord and placenta stem cells via LifebankUSA.
• Future patients suffering from various cancers, immune system dysfunctions, and infectious illnesses, pending regulatory approval of its cell therapies.
• Potential pharmaceutical partners interested in licensing or collaborating on its placental-derived cell therapy platform.

Company Profile

Celularity Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Florham Park, US. The company is led by CEO Robert Joseph Hariri. CELUW has traded publicly since 2021.

Celularity Inc. Financial Trajectory

Celularity Inc. (CELUW) reported $4.1M in revenue for Q4 2025, a decline of 22.3% compared to the prior quarter. The company recorded a net loss of $24.4M, with diluted EPS of $-0.95. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely. Across the four most recent quarters, CELUW averaged $-0.92 in diluted EPS.

How Celularity Inc. Is Valued

Relative to its peer group, CELUW's quantitative score of 50/100 is below the peer average of 76/100.

Return on equity for Celularity Inc. stands at 411.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -85.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -60.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.

Celularity Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.11 places it in the distress zone, a signal of elevated financial risk.

Celularity Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 60.1% above estimates on average.

Wall Street analysts project Celularity Inc. revenue of about $44.0M for fiscal 2026, with EPS near $-2.75.

CELUW Financials

CELUW Latest News

No recent news available for CELUW.

CELUW Analyst Consensus

CELUW MoonshotScore

Common Questions About CELUW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources